Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 15, 2025
December 15, 2025
de07fd31-d42a-4c2e-8af7-ae503e60bcbc
Related Documents
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry
Guidance DocumentDecember 19, 2018Center for Drug Evaluation and Research
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry
Guidance DocumentJuly 27, 2022Center for Drug Evaluation and Research
Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products — Content and Format
Guidance DocumentDecember 10, 2014Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.